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Abstract
Purpose Cryothermal ablation (CTA) for atrioventricular
nodal reentrant tachycardia (AVNRT) is considered safer than
radiofrequency ablation (RFA) since it eliminates the risk of
inadvertent AV block. However, it has not been widely
adopted due to high late recurrence rate (LRR). In an effort
to improve LRR, we evaluated a new approach to cryothermal
mapping (CTM): “time to tachycardia termination” (TTT).
Methods This single-center study had 88 consecutive patients
who underwent CTA using TTT for AVNRT. The CTA cath-
eter was positioned in sinus rhythm at the posteroseptal tricus-
pid annulus, and then AVNRT was induced. The CTA target
site was identified by prompt tachycardia termination in ≤20 s
during CTM. Procedural success was defined as no inducible
AVNRT and ≤1 single AV nodal echoes.
Results Acute procedural success was achieved in 87 of 88
patients (98.9%) and was similar to prior studies for both CTA
and RFA. No permanent AV block was observed. LRR was
3.7 % at a mean follow-up of 19.7 months. LRR was equiv-
alent to that commonly reported for RFA and improved when
compared to conventional CTA.
Conclusion TTT for CTA ofAVNRT provides enhanced safe-
ty and similar long-term efficacy when compared to RFA.
Based upon this experience, TTT provides an enhancement
to conventional CTA that appears to result in improved long-
term outcomes. In light of these findings, it seems reasonable
to undertake additional randomized trials to determine
whether RFA or CTA using TTT is the optimal approach for
the catheter ablation of AVNRT.
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effect . Time to tachycardia termination
Abbreviations
TTT Time to tachycardia termination
TTE Time to effect






LRR Late recurrence rate
1 Introduction
Radiofrequency (RF) catheter ablation is generally con-
sidered the preferred treatment option for patients with
symptomatic atrioventricular nodal reentrant tachycardia
(AVNRT) [1–3]. While its use is associated with excel-
lent short and long-term success rates, a major draw-
back is the risk of inadvertent permanent AV block.
This complication has been reported in up to 2.0 % of
patients [3–6] and leaves them pacemaker-dependent for
life. Given that patients with AVNRT are often young
[1] and free of structural heart disease, this can be a
life-altering complication.
Cryothermal ablation (CTA) is an alternative to radiofre-
quency ablation (RFA) with a similar acute procedural effica-
cy averaging 95 % that also offers the advantage of being
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virtually devoid of the risk of permanent AV block. The initial
experience with CTA for AVNRT was reported in the multi-
center prospective FROSTY trial. None of the 103 patients
with AVNRT that underwent CTA developed inadvertent
AV block that required permanent pacemaker implantation
[7]. Subsequent studies have confirmed this finding in over
1000 patients [8–13].
Despite this noteworthy safety advantage, CTA has not
been broadly adopted as the ablative technique of choice since
its use has been associatedwith a higher risk of late arrhythmia
recurrence [10, 13, 14], averaging 9–10 % for CTA compared
to only 3–4 % for RFA based on the most recent studies [2, 3,
13, 15].
The inherent safety of CTA derives primarily from the re-
versibility of the cryothermal lesion during the first 30–60 s of
cooling when lesion temperature is limited to a nadir of
−30 °C. During this phase of cooling, the targeted tissue be-
comes temporarily unable to conduct, providing the operator
assurance that irreversible CTA at that site will be effective
and unlikely to create permanent AV block. The process of
CTA target site selection is broadly referred to as cryothermal
mapping (CTM). A variety of CTM end-points have been
employed to determine whether a site is suitable for perma-
nent CTA. These include (1) interruption of slow pathway
conduction during CTM; (2) inability to reinduce AVNRT in
a previously inducible patient; and (3) termination of
sustained AVNRT during CTM.
In all previously reported large studies, however, the
exact method employed for CTM was uncontrolled and
left to the discretion of the investigator. Similarly, the time
allowed to achieve the desired CTM effect was uncon-
trolled, often lengthy, and usually not reported. In some
studies, a target site could be deemed appropriate for per-
manent CTA even when the desired effect occurred as late
as 80 s into CTM [13]. Thus, it is possible that the higher
late recurrence rate (LRR) often reported in prior CTA
studies could be related to the CTM methodology
employed. As an example on how the details of the
CTM technique can actually have a significant impact
on outcomes, improved CTA results have been noted
when target site selection was guided by time-limited
CTM, a feature that has often been referred to as “time
to effect” [12, 16, 17].
The objective of our study was to determine if a more
rigorously applied time-limited criterion for CTM success,
namely time to tachycardia termination (TTT), would provide
improved LRR for adult patients undergoing CTA for
AVNRT. Based on the work of previous investigations [12,
16, 17], we defined a successful TTT as the termination of
AVNRT due to slow pathway block within 20 s of the onset
of CTM.
Given the excellent safety profile of CTA, if the LRR seen
with its use could be improved to match that of RFA, it is
reasonable to propose that CTA should become the modality
of choice for patients undergoing catheter ablation for
AVNRT.
2 Methods
2.1 Study design and patient selection
This study enrolled patients with symptomatic AVNRT who
underwent CTA at our center between February 2005 and
June 2011. We attempted to evaluate the utility of TTT during
CTA in 94 consecutive patients. Sustained AVNRT was suc-
cessfully induced in 88 of these 94 patients (94 %). The utility
of TTT as a guide to CTM could therefore be evaluated in
these 88 patients, and they comprised our study population.
In the 6 patients in whom sustained AVNRT could not be
induced, conventional CTM techniques applied during atrial
extrastimulus testing was performed. In all 6 patients, CTA
was successful and none required transition to RFA.
This study was approved by our local institutional review
board. The data collected included patient demographics, ar-
rhythmia characteristics, electrophysiologic study results, pro-
cedural details, complications, as well as acute and long-term
outcomes.
2.2 Electrophysiologic study and cryoablation procedure
CTA was performed with a 7-French 6-mm electrode tip
catheter (Freezor Xtra®, CryoCath Technologies,
Montreal, QC, Canada). In all patients, the target for
CTA was the AV nodal slow pathway, whether it was
utilized in the antegrade or retrograde direction.
Procedure duration was measured from the first venous
sheath placement until final sheath removal.
All procedures were performed by one of three operators. If
CTA was unsuccessful, ablative therapy was transitioned to
the RFA approach.
Electrophysiologic study included the placement of multi-
ple electrode catheters in the standard positions. After record-
ing baseline intervals, antegrade and retrograde properties
were assessed using standard atrial and ventricular pacing
and extrastimulus techniques. Up to three atrial extrastimuli
at multiple cycle lengths were employed. If sustained tachy-
cardia (≥90 s duration) could not be induced, repeat stimula-
tion was undertaken during isoproterenol infusion. The repro-
ducibility of tachycardia induction was confirmed by requir-
ing three separate inductions of ≥90 s duration. AVNRTas the
tachycardia mechanism was confirmed by previously de-
scribed standard techniques [18]. Since December of 2010,
all ablations at our institution have been performed without
fluoroscopic guidance [19]. Catheter positioning was guided
by an electro-anatomic mapping (EAM) system (EnSite
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NavXTM, St. Jude Medical, St. Paul, MN, USA), Therefore,
fluoroscopy times are not reported.
2.3 Cryomapping and cryoablation techniques
After confirmation of the reproducible induction of sustained
AVNRT, the cryoablation catheter was positioned at the
posteromedial tricuspid annulus during sinus rhythm. A site
yielding a distal electrode recording with an A:V ratio of ap-
proximately 1:3 and/or a local slow pathway electrogram was
considered suitable for CTM.
Sustained AVNRTwas again induced. Potential target sites
for permanent CTAwere identified by the ability to terminate
AVNRTwith slow pathway block within 20 s of CTM appli-
cation. Once a suitable target was identified by tachycardia
termination, CTA was continued for a total application time
of 4 min targeting a peak negative temperature of −70 °C.
During CTA application, repeated attempts to induce
AVNRTand to assess the integrity of fast pathway conduction
were undertaken. If tachycardia remained non-inducible and
fast pathway function remained intact, 3 additional “consoli-
dating” lesions guided by EAM were applied immediately
adjacent to the successful site, in an effort to minimize the
extent of the posteroseptal area exposed to permanent injury.
During these “consolidating” applications, AV conduction
was closely monitored and repeated attempts to assess induc-
ibility were undertaken.
If sustained AVNRT could not be terminated within 20 s, a
different site would be selected for CTM. Additionally, if AV
conduction became impaired or re-induction of AVNRT oc-
curred, an alternate site for CTMwas identified. If tachycardia
remained non-inducible after the last consolidation applica-
tion, a 30-min waiting period was required. Thereafter, a re-
peat EP study before and after isoproterenol infusion was un-
dertaken. Procedural end-points for success were defined as
non-inducibility of AVNRTand amaximum of only single AV
nodal reentrant echoes.
2.4 Follow-up
Follow-up was obtained through outpatient clinic records as
well as phone call or mail responses to a questionnaire specif-
ically designed to assess for arrhythmia recurrence. For those
with tachycardia recurrence, follow-up time was measured as
the time in months from the ablation procedure to recurrence.
For those free of recurrence, follow-up was measured as time
from initial procedure to last contact. Six patients were lost to
follow-up and were excluded from the analysis of LRR.
2.5 Statistical analysis
We compared our acute procedural success, LRR, and com-
plication rates to those reported in the major trials on both
CTA and RFA for AVNRT. Data are presented as mean± stan-
dard deviation.
3 Results
3.1 Clinical and demographic features
The clinical, demographic, and arrhythmic features of the par-
ticipants are summarized in Table 1. In total, 11 patients
(12.5 %) had structural heart disease including hypertensive
heart disease, left ventricular systolic dysfunction, myxoma-
tous mitral valve disease, mitral stenosis, aortic stenosis, right
chambers dilatation associated with moderate pulmonary hy-
pertension. Four patients had recurrence of AVNRTafter prior
RFA, and an additional patient had recurrence of AVNRTafter
a prior CTA undertaken at another institution.
3.2 Procedural outcomes
The EP study and CTA outcomes are summarized in Table 2.
Typical slow-fast AVNRT was observed in 79 patients
(90.2 %), while 9 exhibited either the fast-slow or slow-slow
varieties of AVNRT.
The number of CTM attempts before a successful TTT
(≤20 s) was achieved ranged from 1 to 32. Forty-four patients
(50.0 %) required ≤8 CTM attempts and 12 patients required
only one. More than 10 CTM attempts were needed in only 9
patients (10.2 %). Successful CTM was achieved in ≤10 s in
30 patients and in 11 to 20 s in the remaining 57 patients.
A successful CTA using our strict TTT criteria of less than
20 s was achieved in 87 of the 88 patients (98.9 %). For the
remaining 1 patient, the ablation modality was switched to
RFA, which was successful at the same procedure session.
In the 87 patients in whom CTAwas successful, residual dual
nodal physiology with single echoes was observed in 43 pa-
tients and dual pathway physiology was completely eliminat-
ed in the remaining 44 patients.
There were no early or late major procedural complica-
tions. No permanent AV block occurred, but transient AV
block during CTM was noted in 8 patients (9.1 %) and
promptly resolved within 30–180 s upon immediate re-
warming. These sites were identified on the EAM system
and were avoided during subsequent CTA applications. No
further AV conduction disturbances were encountered.
Of the 87 patients in whom acute procedural success was
achieved, 6 were lost to follow-up. Of the remaining 81 pa-
tients, 3 (3.7 %) experienced a recurrence of AVNRT during
long-term follow-up. Time to recurrence ranged from 1 to
26 months (Table 3). The LRR is compared to the results of
other CTA trials in Table 4.
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4 Discussion
4.1 Overview
In this study, we report our center’s acute and long-term pro-
cedural outcomes in 88 consecutive patients in whom we
could use TTT as the guide for CTM success for AVNRT.
CTA, as compared to RFA, offers patients enhanced safety
from procedurally related permanent AV block. Nonetheless,
CTA has not been the preferred method for ablation since its
use has been associated with a significantly higher risk of
LRR. In an effort to retain the safety advantage of CTA, we
evaluated the hypothesis that a reduction in LRR could be
achieved by more rigorously controlling the methodology of
CTM. The changes to CTM that we employed included (1)
performing CTM exclusively during sustained AVNRT and
(2) requiring tachycardia termination in ≤20 s during CTM.
Using this methodology for CTM, acute procedural success
was excellent (98.9 %) and at a mean follow-up of over
19.7 months, the LRR of only 3.7 % was comparable to the
best outcomes reported for patients undergoing RFA [13]. The
results reported in this study suggest that strict control of the
methods used for CTM is essential to achieve improved LRR.
Furthermore, a possible explanation for the wide variation in
LRR often reported for CTA of AVNRTmay well derive from
differences in the methodology employed for CTM (Table 4).
4.2 Prior studies of CTA for AVNRT
Several prior studies of CTA for AVNRT have reported an
unacceptably high LRR which ranged from 8 % to as high
as 17 % [8–13]. Despite the use of apparently similar tech-
niques and study populations, an explanation for this variation
has been lacking. Some have attributed this variance to minor
differences in technique, such as the use of “supplemental”
CTA applications, or the use of larger sized catheter tips. It
had been hoped that the introduction of the larger 6-mm tip, by
providing larger and deeper lesions, would afford improved
LRR. However, as summarized in Table 4, recent studies lim-
ited exclusively to the larger 6-mm tip have still reported LRR
that were unacceptably high when compared to RFA [8–13].
For example, in the largest and most recent of these, the pro-
spective randomized CYRANO trial, the clinical outcomes of
251 patients with AVNRT who underwent CTAwith a 6-mm
catheter tip were compared to those observed in 258 patients
who were treated with standard RFA [13]. While acute proce-
dural success was excellent in both groups, the LRR of 9.4 %
observed for the CTA patients was significantly higher than
the 4.4 % noted in the RFA group. As has been consistently
reported, no permanent AV block was reported for patients
randomized to CTA, while 3 patients (1 %) in the RFA group
developed persistent AV block—one of whom required per-
manent pacing.
A full understanding of the CYRANO trial results, as well
as those reported for other studies involving CTA, requires a
careful examination of the precise methods utilized for the
important variable of CTM. Often the techniques employed
for CTM have been neither tightly controlled nor reported in
detail. Important differences in the techniques of CTM could
potentially explain why some studies have reported long-term
outcomes for CTA equivalent to those seen for RFA, while the
majority of trials have found RFA to be superior. Some im-
portant considerations in the performance of CTM are exam-
ined below.
4.3 Specifics of CTM
The primary goal of CTM is to determine whether a specific
catheter location is optimal for a permanent CTA lesion from
the perspectives of both safety and efficacy. Of the many var-
iables that have been shown to influence the results of CTM,
Table 1 Baseline
characteristics for CTA
using TTT (n= 88)
Mean age 51.6 ± 17
Female 61 (69.3 %)
Male 27 (30.7 %)
Prior RFA for AVNRT 4 (4.5 %)
Prior CTA for AVNRT 1 (1.1 %)
Structural heart disease 11 (12.5 %)
Table 2 Procedural outcomes for CTA using TTT (n= 88)
Acute procedural success 87 (98.9 %)
Cross over from CTA to RFA 1 (1.1 %)
Number of CTA applications 4.2 (3 to 21)
Residual dual AV nodal physiology
None 44 (50 %)
Single echoes 43 (48.8 %)
Inducible AVNRT 1 (1.1 %)
Procedure time in minutes (mean ± SD) 155 ± 68
Complications
Transient complete heart block 3 (3.4 %)
Transient second degree AV block 2 (2.3 %)
Permanent AV block 0 (0.0 %)
Table 3 Long-term arrhythmic outcomes for CTA using TTT (n= 81)
Mean Follow-Up Duration (months) 19.7 ± 23.0
Range (months) 1–110
Late recurrence rate (documented AVNRT) 3.7 % (3/81)
Time to recurrence (months) 1, 1, 26
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two have recently been shown to have direct bearing on the
likelihood of a long-term success. The first is the actual patient
rhythm during which CTM is applied. For example, cooling
during CTM can be applied during atrial pacing runs to assess
slow pathway (SP) function, as is commonly chosen, or sec-
ondly, during induced sustained AVNRT. In the case of atrial
pacing, the effect of CTM on SP conduction is assessed by
repeated pacing runs directed at either inducing AVNRT or
confirming impairment or elimination of SP function. When
CTM is applied during induced sustained tachycardia, termi-
nation of AVNRT is the determinant of CTM success. It is
likely that termination of AVNRT was a result of SP block
as opposed to AV nodal block in that the integrity of both
AV nodal and fast pathway conduction was confirmed imme-
diately upon the resumption of sinus rhythm and, additionally,
during subsequent atrial pacing runs applied shortly after
tachycardia termination.
The second important variable in selecting an optimal ab-
lation site is time: specifically, time to effect (TTE) defined as
the duration of cooling to −30 ° C before the desired effect is
achieved. In virtually all prior randomized trials comparing
CTA and RFA, a TTE of up to 60 s was considered an accept-
able duration [7, 13]. In this approach, either the lack of in-
ducibility or the elimination/impairment of SP function, with-
in the specified time frame of test cooling, is considered a
favorable CTM result and indicates a site suitable for perma-
nent CTA. The TTE at a given test site is a measure of catheter
tip proximity to the targeted tissue. Given the smaller and
more discrete lesion size associated with CTA, the use of a
narrow window for TTE is likely to be indicative of greater
proximity to the SP and a higher probability of achieving
permanent interruption of SP function and long-term arrhyth-
mia suppression.
In several recent studies, investigators have emphasized the
importance of TTE during CTM as a determinant of LRR [12,
17]. In 30 pediatric patients with SVTs and right sided acces-
sory pathways, Drago and colleagues were able to show a
lower LRR of only 5.9 % when TTE was less 10 s, compared
to greater than 20% in those with a more prolonged TTE [17].
In a much larger study of 312 adults with slow-fast AVNRT,
Bastani and colleagues strictly controlled CTM by limiting
TTE to a maximum duration of 20 s. Acute procedural success
was 99 %, and, importantly, the LRR improved to 5.8 % at an
average follow-up of 6 years [12]. The observed decrease in
LRR was in part attributed to the strict time criterion used to
define a successful CTM response.
The ability to determine a precise TTE can be further en-
hanced by the performance of CTM during induced tachycar-
dia. This approach allows for an unambiguous determination
of TTE as indicated by the abrupt termination of tachycardia
due to failure of SP conduction. In contrast, the performance
of CTM during various atrial pacing maneuvers renders an
accurate determination of TTE more difficult because the pac-
ing maneuver itself consumes time. In addition, the ability to
achieve consistent SP conduction is often variable from one
pacing attempt to another, which further impedes the ability to
determine a precise TTE. Lastly, the presence of multiple SPs
is not infrequent and the prompt termination of tachycardia
ensures that the pathway supporting the tachycardia is in fact
the one being targeted for permanent CTA [20].
4.4 Additional contributors to improved LRR
While the most likely explanations for the improved LRR
observed in this study derive from the strict time-limited cri-
terion used to guide CTM results and the performance of
CTM during sustained AVNRT, other variables could have
contributed as well. Three consecutively applied “consolida-
tion” lesions were delivered. These applications were guided
by EAM and located as close as possible to the initial success-
ful site. In the CYRANO study, only one supplemental appli-
cation was used [13]. The extent to which our additional
consolidative CTA applications or the use of EAM contribut-
ed to our lower LRR is difficult to determine.
A remaining variable that could have influenced long-term
outcome is that we routinely employed isoproterenol stimula-
tion after an “apparently” successful initial CTA—even in
patients who did not require its use for the induction of















Jensen-Urstad M, et al.
[8]
2006 75 9.2 53 ± 16 6 99 7 0
Khairy, et al. [9] 2007 185 24 49 ± 14 6 92 9 0
De Sisti, et al. [10] 2007 150 18± 10 39 ± 14 6 95 17 0
Chan, et al. [11] 2009 80 – 50 ± 12 6 97.5 9 0
Bastani, et al. [12] 2009 312 22± 10 22 ± 10 6 99 5.8 0
Deisenhofer, et al. [13] 2010 251 6 50 ± 15 6 97 9.4 0
CTA using TTT 2016 88 19.7 ± 23.0 51.6 ± 17 6 98.9 3.7 0
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AVNRT in the baseline state. This additional step extended the
duration of post CTA observation and, thereby, could have
facilitated our ability to detect delayed recovery of SP func-
tion. In this study, we did not determine the extent to which
this additional step led to further CTA applications.
4.5 Study limitations
The primary limitation of our study is that it is a single-center,
non-randomized trial. Additionally, our results are compared
to those reported in previous trials—some recent, but also
some more remote. Accordingly, it is possible that a patient
selection bias may have in some way contributed to the favor-
able long-term outcome observed in our study population.
While the sample study size of our study was modest, all of
the 88 patients included in this study were consecutively en-
rolled and reflect all patients with AVNRT referred to our
center for catheter ablation during the study interval.
Also, there are certain requirements inherent in the ap-
proach we employed in this study. First, it requires that pa-
tients exhibit, in a reproducible fashion, sustained AVNRT.
This step will often necessitate the use of isoproterenol stim-
ulation. In our experience, about 6–7 % of patients with doc-
umented AVNRT will fail to exhibit sustained tachycardia at
the time of the procedure. In this situation, some other ap-
proach to CTM will be required. In such patients, CTM can
usually be undertaken during atrial pacing maneuvers to as-
sess impairment of SP function as described above [12, 13].
While it may bemore difficult to determine a precise TTE, this
approach can still be employed and used to achieve procedural
success.
When compared to the CTA arm of the CYRANO trial, our
procedure time was on average 14 min longer. This slightly
longer procedure time can be largely accounted for by the 2
additional 4-min consolidating applications we employed and
the use of isoproterenol infusion in all patients at the conclu-
sion of the procedure. It is unlikely this small an extension of
procedure time would have any significant clinical impact.
5 Conclusions
Our study results suggest that CTA for AVNRT, contrary to
the widely held perception, need not be associated with a
higher likelihood of LRR. TTT represents a technical refine-
ment when compared to conventional CTM. The performance
of CTM during sustained AVNRTwith the use of a strict TTT
criterion of ≤20 s may have been the essential step needed to
achieve this improvement. In fact, the LRR of only 3.7 %
noted in our study is comparable to the 4.4 % rate noted in
the recent CYRANO trial for RFA and is superior to the 9.4 %
rate these investigators observed in their CTA group. Our
findings, combined with those noted by others [12, 13],
suggest that future trials of CTA for AVNRT should employ
at least some of the strict CTM criteria used in our study.
These results will need to be confirmed, optimally in a
controlled randomized trial, before a formal recommendation
can be made. Admittedly, the risk of permanent AV block
when RFA is used in this setting is low (0.4–2.0 %).
However, given the large number of patients who are likely
to undergo RFA for AVNRT in the future, many may be
spared the risk of life-long permanent pacemaker dependence
if CTA becomes the preferred initial approach to catheter ab-
lation of AVNRT.
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